MOH Stock Recent News

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH).

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).

Barclays analyst Andrew Mok raised the firm's price target on UnitedHealth to $362 from $337 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays lowered the firm's price target on Molina Healthcare to $185 from $186 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 23 Oct

Barclays analyst Andrew Mok raised the firm's price target on Humana to $325 from $275 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays raised the firm's price target on Elevance Health to $373 from $327 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 11 Sep

Barclays analyst Andrew Mok raised the firm's price target on CVS Health to $87 from $80 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.

Barclays raised the firm's price target on Cigna to $383 from $354 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk. 30 Oct

Barclays analyst Andrew Mok lowered the firm's price target on Centene to $33 from $45 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthcare facility group following a "volatile" Q2 earnings season. Group valuations have increased recently, which may be a sign that investor sentiment and estimates have bottomed out, the analyst tells investors in a research note. From here, Barclays sees a number of potential catalysts including September budget deals, final pricing for Medicare Advantage and Affordable Care Act plans and Medicare Advantage star ratings for the 2027 plans. Relative to estimates, the firm believes UnitedHealth (UNH) and CVS Health (CVS) offer the most near-term upside while Molina Healthcare (MOH) has the most downside risk.